

FORM PTO-1449
(REV. 7-80)

ATTY. DOCKET NO.

KIR92-01A3

SERIAL NO.

08/607,419

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANTS

Marc Feldmann, Ravinder N. Maini
and Richard O. Williams

FILING DATE

February 28, 1996

GROUP

RECEIVED

1806

SEP 16 1996

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	GROUP	FILE DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 89/08460	21-SEP-89	PCT			
	AM	WO 92/08474	29-MAY-92	PCT			
	AN	WO 92/07585	14-MAY-92	PCT			
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	AR	Horneff, G., et al., "Elevated levels of circulating tumor necrosis factor- α , interferon- γ , and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis", Cytokine, 3(3):266-247 (1991).
	AS	Brennan, F., et al., "Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", The Lancet, 2(8657):244-247 (1989).
	AT	Steinbruchel, D., et al., "Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporin A has a positive but not simple dose-dependent effect on rat renal allograft survival", Scandinavian J. of Immunol., 34(5):627-633 (1991).


EXAMINER

Phillip G. Smith

DATE CONSIDERED

12/4/97

FORM PTO-1449 (REV. 7-80) INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				ATTY. DOCKET NO. KIR92-01A3		SERIAL NO. 08/607,419	
				APPLICANTS Marc Feldmann, Ravinder N. Maini and Richard O. Williams			
				FILING DATE February 28, 1996		GROUP 1806	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AU	Breedveld, F., et al., "Anti-CD4 antibodies in rheumatoid arthritis", <i>Clinical and Experimental Rheumatology</i> , 10(4): 325-326 (1992).					
	AV	Brennan, F., et al., "TNF α -a pivotal role in rheumatoid arthritis?", <i>British J. Rheumatology</i> , 31(5):293-298 (1992).					
	AW	Elliott, M.J., et al., "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF- α : safety, clinical efficacy and control of the acute phase response", <i>Cell. Biochemistry, Supplement</i> , 0(17B):145 (1993); Abstract EZ405.					
	AX	Williams, R.O., et al., "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis", <i>Proc. Natl. Acad. Sci. USA</i> , 91:2762-2766 (1994).					
	AY	Ralph, P., "Clinical and Preclinical Studies Presented at the Keystone Symposium on Arthritis, Related Diseases, and Cytokines," <i>Lymphokine and Cytokine Research</i> , 12(4):261-263 (1993).					
	AZ	Racadot, E., "Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5)," <i>Clinical and Experimental Rheumatology</i> , 10:365-374 (1992).					
	AR2	Williams, R.O., et al., "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4," <i>Immunology</i> , 84:433-439 (March 1995).					
	AS2	Van Der Lubbe, P.A., et al., "A Randomized, Double-Blind, Placebo-Controlled Study of CD4 Monoclonal Antibody Therapy In Early Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> , 38(8): 1097-1106 (1995).					
EXAMINER				DATE CONSIDERED			
PHILIP GAMBEL				12/4/97			



FORM PTO-1449 (REV. 7-80) INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		ATTY. DOCKET NO. KIR92-01A3		SERIAL NO. 08/607,419	
		APPLICANTS: Marc Feldmann, Ravinder N. Maini and Richard O. Williams			
		FILING DATE February 28, 1996		GROUP 1806	
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUB- CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	AT2	Choy, E.H.S., et al., "Therapeutic Monoclonal Antibodies," <i>British J. Rheumatology</i> , 34:707-715 (1995).			
	AU2	Rankin, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Antibody (CDP571) in Rheumatoid Arthritis," <i>British J. Rheumatology</i> , 34: 334-342 (1995).			
	AV2	Butler, D.M., et al., "Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF- α antibody with the interleukin-1 receptor antagonist," <i>Eur. Cytokine Netw.</i> , 6(4): 225-230 (1995).			
	AW2	Horneff, G., et al., "Treatment of Rheumatoid Arthritis with an Anti-CD4 Monoclonal Antibody," <i>Arthritis & Rheumatism</i> , 34(2): 129-140 (1991).			
	AX2	Van Dullemen, H.M., et al., "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> , 109(1):129-135 (1995).			
	AY2	Watts, R.A., and Isaacs, J.D., "Immunotherapy of rheumatoid arthritis," <i>Annals Rheumatic Diseases</i> , 51:577-579 (1992).			
	AZ2	Schacht, E., "Gegenwärtige und zukünftige Therapiestrategien der rheumatoiden Arthritis (RA)*" ["The current and future therapy strategies of rheumatoid arthritis (RA)], <i>Zeitschrift für Rheumatologie</i> , 52(6):365-382 (1993). <i>summary only</i>			
EXAMINER Philip Gammel			DATE CONSIDERED 12/4/97		

[illegible]